How to Structure a Board Paper Proposing an Acquisition in a Regulated Sector

An acquisition paper in a regulated sector is not a transaction memo with a governance wrapper. It is the document the board will be measured against for years, by auditors, by supervisors, and in some cases by a court. If it reads like a sales pitch, you have already lost the room that matters.

Start with the decision, not the deal

Open the paper with a one page decision summary: what the board is being asked to approve, on what terms, by when, and what it is not being asked to approve. Boards often sign off on acquisitions and later discover they also implicitly approved a funding structure, a brand decision, or a regulatory commitment nobody flagged. Separate these explicitly. If approval is conditional, state the conditions in binding language.

Then state the strategic rationale in plain terms. Why this target, why now, why not organic growth, why not an alternative target. If the honest answer includes defensive motivations or management ambition, acknowledge it. Papers that overclaim strategic fit are the ones that unravel under non executive challenge.

Build the regulatory analysis into the thesis

In a regulated sector, regulatory treatment is part of the deal economics, not a compliance appendix. The paper should address, with substance:

• Change in control approvals required, in which jurisdictions, and the realistic timeline including pre notification engagement already undertaken.
• Prudential impact: capital, liquidity, MREL or equivalent, Pillar 2 implications, and whether the combined entity sits comfortably inside risk appetite or requires it to be reset.
• Conduct and customer outcomes, including any legacy issues in the target's book that will transfer with the business.
• Operational resilience, third party dependencies, and data implications, particularly where the target runs on infrastructure that will need to be integrated or replaced.
• Recovery and resolution consequences, including whether the acquisition changes the group's resolution strategy.

If you have engaged with supervisors informally, say so, summarise the substance, and attach the correspondence. Boards should never learn about regulatory concerns from the regulator.

Price, structure and the alternatives

Show the valuation range, the key sensitivities, and the point at which the deal stops making sense. Identify who did the work, what assumptions they relied on, and where the independent challenge came from. If management and the advisers agree on everything, that is a signal, not a reassurance.

Set out the structure: cash, equity, earn out, warranties, indemnities, and any regulatory capital treatment of the consideration itself. Explain what happens to the capital ratios on day one, day 365, and under stress.

Include a credible alternatives section: the next best target, a bolt on strategy, buyback, or doing nothing. If the alternatives have not been seriously analysed, the recommendation lacks a baseline.

The downside case and the walk away

This is where most papers are weakest. Present the downside case with the same specificity as the base case: integration failure, customer attrition, technology cost overrun, regulatory remediation of inherited issues, key person loss. Quantify where you can, describe where you cannot.

Then state the walk away conditions. What due diligence findings, regulatory responses, or market events would cause management to recommend abandoning the transaction. A paper without walk away triggers invites a board to approve a direction of travel rather than a decision.

Integration, governance, and the first hundred days

Close with how the acquisition will be governed post completion: the integration committee, reporting lines to the board, the risk and audit touchpoints, and the metrics against which success will be measured. Name the accountable executive. Set the review date at which the board will formally reassess the thesis against outcomes.

Next step

Before circulating the draft, ask whether a well prepared non executive could, from this paper alone, explain the deal, the risks, and the conditions for approval to a supervisor. If not, it is not ready.

Frequently Asked Questions

How long should the paper be?

Long enough to support the decision, short enough to be read. For a material acquisition, expect a core paper of twenty to forty pages with structured appendices. The decision summary should be one page and should stand alone.

When should the board first see the transaction?

Well before the approval meeting. A single paper arriving cold for sign off is a governance failure. Use an earlier session to test strategic rationale and risk appetite implications, so the approval meeting is about terms and conditions, not concept.

How do we handle disagreement among advisers?

Surface it. If the financial adviser, the lawyers, and internal risk disagree on a material point, the board needs to see the disagreement and the reasoning, not a reconciled summary that hides it.

What about confidentiality and insider lists?

Manage distribution tightly and document it. The paper itself should assume it will be read later by people who were not in the room, including supervisors and auditors. Write it accordingly.

Who should draft the paper?

The accountable executive, supported by the deal team, with meaningful input from the CRO and General Counsel before it reaches the board. If the CRO sees the paper for the first time at the meeting, the governance has already broken.